FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894507908> ?p ?o ?g. }

• W2894507908 abstract "Abstract Background Skin infections are a significant medical burden for affected individuals and the healthcare system. The purpose of this investigation was to integrate the findings of two randomized studies of omadacycline (OMC) in ABSSSI. Methods OMC in Acute Skin and Skin Structure Infections Study (OASIS)-1 initiated patients on intravenous (IV) OMC or linezolid (LZD) with a possible transition to oral formulation after at least 3 days of IV therapy. OASIS-2 investigated oral-only OMC. Treatment duration in both studies was 7–14 days. Early clinical response (ECR) in the mITT population, the primary endpoint in both studies, was defined as a ≥20% reduction in lesion size at 48–72 hours after treatment initiation. The secondary endpoint was investigator assessment of clinical response (IACR) at post-therapy evaluation (PTE) in the mITT and CE populations, 7–14 days after treatment initiation. Results A total of 691 patients receiving OMC and 689 patients receiving LZD were included. The mean age of patients was 45 years, 64% were male, and 83% enrolled at US sites. Infection types: wound infections (46.8%), cellulitis/erysipelas (30.5%), major abscess (22.7%). Median lesion size was 316 cm2 and 304 cm2 in OMC and LZD patients, respectively. S. aureus was detected in 74.6% of patients, of which 43.4% had MRSA. 71% were mono-microbial Gram-positive infections, 15% were poly-microbial Gram-positive infections. OMC showed similar efficacy to LZD for the primary and secondary endpoints, as well as for mono-microbial and poly-microbial infections (figure). Clinical responses were similar across different infection types, lesion sizes, and baseline pathogens. Treatment-emergent adverse events (TEAEs), most mild or moderate, were reported by 51% and 41% of patients receiving OMC or LZD, respectively. Nausea and vomiting were more frequent for OMC patients in the OASIS-2 oral-only study while receiving the loading dose on Day 1 and 2. Serious AEs were reported by 2.3% and 1.9%, respectively. TEAEs leading to study drug discontinuation were reported by 1.7% and 1.5%, respectively. Conclusion The integrated analysis of OASIS trials showed that oral and IV omadacycline was effective in the treatment of ABSSSI and was safe and generally well-tolerated by patients. Disclosures F. M. Abrahamian, Allergan: Speaker’s Bureau, Speaker honorarium. Melinta: Speaker’s Bureau, Speaker honorarium. Merck: Speaker’s Bureau, Speaker honorarium. Nabriva: Scientific Advisor, Consulting fee. Paratek: Scientific Advisor, Consulting fee. G. Sakoulas, Allergan: Consultant and Speaker, Consulting fee and Speaker honorarium. Sunovion Pharmaceuticals: Speaker, Speaker honorarium. The Medicines Company: Speaker, Speaker honorarium. Paratek Pharmaceuticals: Consultant, Consulting fee. Cidara Therapeutics: Scientific Advisor, Consulting fee. Arsanis Pharmaceuticals: Scientific Advisor, Consulting fee. E. Tzanis, Paratek Pharmaceuticals: Employee, Salary. A. Manley, Paratek Pharmaceuticals: Employee and Shareholder, Salary. J. N. Steenbergen, Paratek Pharmaceuticals: Employee and Shareholder, Salary. A. Das, Achaogen: Consultant, Consulting fee. Cempra: Consultant, Consulting fee. Contrafect: Consultant, Consulting fee. Nabriva: Consultant, Consulting fee. Paratek: Consultant, Consulting fee. Tetraphase: Consultant, Consulting fee. Theravance: Consultant, Consulting fee. Wockhardt: Consultant, Consulting fee. P. Eckburg, Paratek: Consultant, Consulting fee. P. McGovern, Paratek Pharmaceuticals: Employee, Salary." @default.
• W2894507908 created "2018-10-05" @default.
• W2894507908 creator A5017445754 @default.
• W2894507908 creator A5031780287 @default.
• W2894507908 creator A5043695605 @default.
• W2894507908 creator A5048092291 @default.
• W2894507908 creator A5053622214 @default.
• W2894507908 creator A5056094682 @default.
• W2894507908 creator A5083112115 @default.
• W2894507908 creator A5089036530 @default.
• W2894507908 date "2018-11-01" @default.
• W2894507908 modified "2023-09-25" @default.
• W2894507908 title "1347. Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials" @default.
• W2894507908 doi "https://doi.org/10.1093/ofid/ofy210.1178" @default.
• W2894507908 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6253360" @default.
• W2894507908 hasPublicationYear "2018" @default.
• W2894507908 type Work @default.
• W2894507908 sameAs 2894507908 @default.
• W2894507908 citedByCount "3" @default.
• W2894507908 countsByYear W28945079082019 @default.
• W2894507908 crossrefType "journal-article" @default.
• W2894507908 hasAuthorship W2894507908A5017445754 @default.
• W2894507908 hasAuthorship W2894507908A5031780287 @default.
• W2894507908 hasAuthorship W2894507908A5043695605 @default.
• W2894507908 hasAuthorship W2894507908A5048092291 @default.
• W2894507908 hasAuthorship W2894507908A5053622214 @default.
• W2894507908 hasAuthorship W2894507908A5056094682 @default.
• W2894507908 hasAuthorship W2894507908A5083112115 @default.
• W2894507908 hasAuthorship W2894507908A5089036530 @default.
• W2894507908 hasBestOaLocation W28945079081 @default.
• W2894507908 hasConcept C126322002 @default.
• W2894507908 hasConcept C141071460 @default.
• W2894507908 hasConcept C16005928 @default.
• W2894507908 hasConcept C168563851 @default.
• W2894507908 hasConcept C203092338 @default.
• W2894507908 hasConcept C2777238321 @default.
• W2894507908 hasConcept C2778980435 @default.
• W2894507908 hasConcept C2779489039 @default.
• W2894507908 hasConcept C2781414143 @default.
• W2894507908 hasConcept C2908647359 @default.
• W2894507908 hasConcept C501593827 @default.
• W2894507908 hasConcept C523546767 @default.
• W2894507908 hasConcept C535046627 @default.
• W2894507908 hasConcept C54355233 @default.
• W2894507908 hasConcept C71924100 @default.
• W2894507908 hasConcept C86803240 @default.
• W2894507908 hasConcept C89423630 @default.
• W2894507908 hasConcept C90924648 @default.
• W2894507908 hasConcept C99454951 @default.
• W2894507908 hasConceptScore W2894507908C126322002 @default.
• W2894507908 hasConceptScore W2894507908C141071460 @default.
• W2894507908 hasConceptScore W2894507908C16005928 @default.
• W2894507908 hasConceptScore W2894507908C168563851 @default.
• W2894507908 hasConceptScore W2894507908C203092338 @default.
• W2894507908 hasConceptScore W2894507908C2777238321 @default.
• W2894507908 hasConceptScore W2894507908C2778980435 @default.
• W2894507908 hasConceptScore W2894507908C2779489039 @default.
• W2894507908 hasConceptScore W2894507908C2781414143 @default.
• W2894507908 hasConceptScore W2894507908C2908647359 @default.
• W2894507908 hasConceptScore W2894507908C501593827 @default.
• W2894507908 hasConceptScore W2894507908C523546767 @default.
• W2894507908 hasConceptScore W2894507908C535046627 @default.
• W2894507908 hasConceptScore W2894507908C54355233 @default.
• W2894507908 hasConceptScore W2894507908C71924100 @default.
• W2894507908 hasConceptScore W2894507908C86803240 @default.
• W2894507908 hasConceptScore W2894507908C89423630 @default.
• W2894507908 hasConceptScore W2894507908C90924648 @default.
• W2894507908 hasConceptScore W2894507908C99454951 @default.
• W2894507908 hasLocation W28945079081 @default.
• W2894507908 hasLocation W28945079082 @default.
• W2894507908 hasLocation W28945079083 @default.
• W2894507908 hasOpenAccess W2894507908 @default.
• W2894507908 hasPrimaryLocation W28945079081 @default.
• W2894507908 hasRelatedWork W1979814052 @default.
• W2894507908 hasRelatedWork W1995734689 @default.
• W2894507908 hasRelatedWork W2069898647 @default.
• W2894507908 hasRelatedWork W2273765082 @default.
• W2894507908 hasRelatedWork W2306869911 @default.
• W2894507908 hasRelatedWork W3048542502 @default.
• W2894507908 hasRelatedWork W3096266033 @default.
• W2894507908 hasRelatedWork W4239372735 @default.
• W2894507908 hasRelatedWork W4254873301 @default.
• W2894507908 hasRelatedWork W2083697902 @default.
• W2894507908 isParatext "false" @default.
• W2894507908 isRetracted "false" @default.
• W2894507908 magId "2894507908" @default.
• W2894507908 workType "article" @default.